Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer
A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies
NON-breast HER2+ Malignancies
DRUG: NJH395
Incidence and severity of dose limiting toxicities (DLTs), The time frame will expand to 42 days for the second part of the study, 21 days|Number of participants with Adverse Events, 2.5 years
Concentration versus time profiles for NJH395 and its catabolite, 126 days|PK parameter (Cmax) for NJH395, 126 days|Pharmacokinetic (PK) parameter (AUC) for NJH395, 126 days|Incidence of anti-NJH395 antibodies and neutralizing antibodies to trastuzumab, 126 days|Overall Response Rate, Response assessed by RECIST v1.1 and iRECIST, 2.5 years|Clinical Benefit Rate (CBR), Response assessed by RECIST v1.1 and iRECIST, 2.5 years|Progression Free Survival (PFS), Time from start of treatment to date of the first documented progression or death in months, 2.5 years|Duration of Response (DOR), Response assessed by RECIST v1.1 and iRECIST, 2.5 years|Characterization of tumor-infiltrating lymphocytes by IHC, Change from baseline in TILs by immunohistochemistry (IHC) (such as CD8)., Cycle 1 Day 5, Cycle 2 Day 1 (each cycle is 21 days), Cycle 8 Day 1 and at end of treatment (expected between months 6 and 7)
This study has two parts. There will be a single dose of NJH395 in the first part and multiple doses of NJH395 in the second part. After the first part is completed, the second part may open.